Hakami Alqassem Y, Felemban Razaz, Ahmad Rami Ghazi, Al-Samadani Abdulrahman H, Salamatullah Hassan K, Baljoon Jamil M, Alghamdi Loay J, Ramadani Sindi Mostafa H, Ahmed Mohamed Eldigire
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Front Psychiatry. 2022 May 24;13:914165. doi: 10.3389/fpsyt.2022.914165. eCollection 2022.
Obesity and its complications are associated with several adverse effects that may cause a serious impact on health. Antipsychotics-induced weight gain (AIWG) is one of the major, yet often neglected side effects of first and second generations antipsychotics. Importantly, several researches have shown metformin to be effective in managing weight gain especially, with AIWG. This study investigated the effect of antipsychotics use on weight gain and the theory of metformin concomitant use on the prevention of AIWG.
A retrospective cohort review of the medical records of patients from the psychiatry outpatient clinics in the King Abdulaziz Medical city, a tertiary hospital in Jeddah from May 2016 to August 2021. The population of patients in Psychiatry section was 4,141. The sampling technique was a non-random consecutive sampling technique. Moreover, the included patients' records were divided to group 1 (patients on antipsychotics) and group 2 (patients using antipsychotics with Metformin).
According to the study criteria, 395 patients' records were included. A total of 309 (78%) patients were using antipsychotics without metformin, which in this study were depicted as group 1. In addition, a total of 86 (22%) were using antipsychotics with metformin, which in this study were assigned as group 2. Out of Group 1 patients ( = 309), only 67 patients experienced weight loss (21.68%), 43 remained with no weight change (13.92%), and 199 experienced weight gain (64.4%). Out of Group 2 patients ( = 86), 35 patients experienced weight loss (40.7%), 18 patients remained with no weight change (20.93%), and 33 experienced weight gain (38.37%). In addition, group 1 had a mean weight change of 2.5 kg, whereas group 2 had a mean weight change of -0.04 kg.
Statistical analysis revealed that patients on antipsychotics alone experienced weight gain, whereas the concomitant use of metformin showed reduction in the weight gain tendency. Thus, study outcomes indicate that concomitant use of metformin with antipsychotics might significantly reduce the AIWG.
肥胖及其并发症会带来多种不良影响，可能对健康造成严重冲击。抗精神病药物所致体重增加（AIWG）是第一代和第二代抗精神病药物的主要副作用之一，但常常被忽视。重要的是，多项研究表明二甲双胍在控制体重增加方面有效，尤其是对于抗精神病药物所致体重增加。本研究调查了使用抗精神病药物对体重增加的影响以及二甲双胍联合使用预防抗精神病药物所致体重增加的理论。
对吉达一家三级医院阿卜杜勒阿齐兹国王医疗城精神科门诊患者的病历进行回顾性队列研究。研究时间为2016年5月至2021年8月。精神科患者总数为4141人。抽样技术为非随机连续抽样技术。此外，将纳入患者的记录分为第1组（使用抗精神病药物的患者）和第2组（使用抗精神病药物联合二甲双胍的患者）。
根据研究标准，纳入395份患者记录。共有309名（78%）患者在未使用二甲双胍的情况下使用抗精神病药物，在本研究中被描述为第1组。此外，共有86名（22%）患者在使用抗精神病药物的同时使用二甲双胍，在本研究中被指定为第2组。在第1组患者（n = 309）中，只有67名患者体重减轻（21.68%），43名患者体重无变化（13.92%），199名患者体重增加（64.4%）。在第2组患者（n = 86）中，35名患者体重减轻（40.7%），18名患者体重无变化（20.93%），33名患者体重增加（38.37%）。此外，第1组的平均体重变化为2.5千克，而第2组的平均体重变化为-0.04千克。
统计分析显示，单独使用抗精神病药物的患者体重增加，而联合使用二甲双胍则显示体重增加趋势有所降低。因此，研究结果表明，二甲双胍与抗精神病药物联合使用可能会显著降低抗精神病药物所致体重增加。
